Genomic surveillance — the process of monitoring and sequencing pathogens — is one of the most important tools for detecting emerging viral threats. But global surveillance systems remain costly, unevenly distributed and often are too slow to identify dangerous variants before they spread internationally,  amplifying future threats of disease outbreaks.

A recently published research paper in Nature Communications, co-authored by Dr. Patricia Ning, assistant statistics professor, and Jifan Li, a doctoral candidate in the Department of Statistics, along with collaborators from multiple international institutions, introduces a new framework to rectify these issues while using fewer resources, making genomic surveillance rapid and cost-effective in preparation for new strains of COVID-19.

A recent study led by Professor Zhao Lichun（赵立春）from the Research Center of Trace Elements and Health Development at Guizhou University of Traditional Chinese Medicine was published in the World Journal of Integrated traditional and western Medicine (WJIM), entitled “Theoretical Framework and Hypothesis on the Association Between Rubidium Ion Metabolic Dysregulation and Parkinson’s Disease.” This work, grounded in ionic homeostasis imbalance as a fundamental biophysical process, proposes an integrated theoretical model spanning “ion regulation-cellular dysfunction-neurodegeneration,” thereby providing a novel interpretative dimension and potential intervention perspective for the pathogenesis of Parkinson’s disease (PD).

Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized. By combining genetic and proteomic analyses, the scientists were able to identify biological characteristics of tumors, particularly in high-risk patients for whom standard therapy offers little chance of cure. In the future, such patients could receive alternative, more effective therapies directly. In addition, experimental laboratory research provided initial clues to potential therapeutic targets.

July 7-10, 2026 | Geneva

Dr. Alex Aliper, Co-founder and President of Insilico Medicine, will attend the AI for Good Global Summit 2026 in Geneva, Switzerland, on July 7.

July 8, 2026 | Beijing

Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the CITICS Global Consumer and Healthcare Forum 2026 in Beijing on July 8.

July 8-10, 2026 | Hong Kong

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend the international science, technology, and information technology exhibition, LEAP EAST, held in Hong Kong from July 8 to 10.

Coastal wetlands are among the most powerful carbon sinks on the planet, but a new study reveals that the standard methods used to measure this stored carbon may be systematically underestimating uncertainty in coastal zones. 

Chinese researchers led by Prof. Shen Liu from the Department of Orthopedics of the Shanghai Jiao Tong University School of Medicine have discovered that certain supporting cells expressing a protein marker called p16^INK4a, once associated with aging or stressed cells, were found to be key drivers of tendon healing. JMJD3, a molecular "switch," helped them turn on the repair genes. This pathway can be targeted to develop new treatment strategies for tendon injuries.

The AKI-PURIFY survey provides a contemporary international overview of acute kidney injury (AKI) prevention and management practices in ICUs. Despite evidence supporting structured KDIGO-based preventive strategies, implementation remains inconsistent worldwide. Educational gaps, organizational barriers, and resource disparities significantly influence the adoption of evidence-based care. The survey highlights marked heterogeneity in diagnostic and renal replacement therapy practices, emphasizing the need for scalable training programs, audit systems, and context-sensitive implementation frameworks to improve AKI outcomes globally.